France Legalizes CBD Cannabis Derived Products with THC below 0.3%

Jan.06.2023
France Legalizes CBD Cannabis Derived Products with THC below 0.3%
France legalizes sales of CBD-derived products with THC up to 0.3% but still bans sales of unprocessed cannabis flowers.

According to French media outlet RFI, on December 30th, 2021, the French government legalized the sale of cannabis-derived products containing CBD, with a THC content of no more than 0.3%, one year after lifting the ban on CBD. However, cannabis enthusiasts and those who favor Delta-8 (D8) may be disappointed to learn that the government still prohibits the sale of cannabis flowers, citing their supposed psychoactive effects.


However, a high court in France overturned the ban, ruling that CBD has not been proven harmful and that there are other legal uses for the plant besides smoking.


On December 29th, the French State Council (an institution that provides legislative proposals to the government and serves as the highest court) ruled that a comprehensive and absolute ban on the sale of raw forms of CBD was "disproportionate." They also found no conclusive evidence of harm from CBD. If any evidence exists, it is to the contrary.


The harmful effects of other molecules present in cannabis flowers and leaves, particularly CBD, have not yet been determined," the committee said. The committee added that there is evidence to suggest that CBD has "relaxing properties and anti-seizure effects, but no psychoactive effects, nor does it cause dependency.


In other words, the court ruled that marijuana should not automatically be classified as a psychoactive drug, as this is far from the truth. Additionally, it can be used not only for smoking, but also for making tea or infused oil. Other factors to consider are homemade tinctures or vaporizing the flowers.


Concerns about distinguishing between different types of cannabis.


Despite the recent court ruling allowing for cannabis cultivation, concerns have been raised about the government's plans to distinguish between cannabis and its highly potent derivative, tetrahydrocannabinol (THC), which is nearly indistinguishable to the naked eye. The State Council maintains that THC levels "can be controlled through rapid testing.


In November 2020, the European Court ruled that a ban on CBD that is legal in other European countries is illegal in France, based on the principle of free movement of goods.


The highest court of justice in France ruled in June of last year that any CBD produced legally in the European Union can be sold legally in France.


According to the French Professional Cannabis Association (SPC), as reported by RFI, there are now approximately 2,000 CBD shops operating in France. The industry's annual turnover is estimated to be around €500 million, or $534.1 million USD. More than half of these sales come solely from flowers.


Experts in the country have stated that the latest court ruling provides a green light for the economically sustainable cannabis industry that can withstand the test of time.


According to a report by Hemp Today, the French Senate committee has stated that legalizing cannabis in France could generate an annual revenue of 1.5 euros (160 billion USD) to 2.5 billion euros (260 billion USD) and create between 18,000-20,000 job opportunities.


The French extractive trade group, UIVEC, estimates that the grey market for CBD in France will be worth around 200 million euros ($214 million) by 2021, and is expected to reach about 300 million euros ($321 million) this year. UIVEC also estimates that by 2022, approximately 300-500 hectares of cannabis will be grown for hemp flower CBD production.


As legislation moves forward, these regulations are expected to be implemented in early 2023. The government is expected to announce that marijuana is in compliance with the European Union's common agriculture policy, develop an industry strategy, and create specific regulations.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Influential Islamic Body MUI Urges Vape Permit Freeze, Raising Uncertainty for 200 Manufacturers
Indonesia's Ulema Council (MUI) published Fatwa No. 131/2026 on November 9, declaring electronic cigarette use, production and trade haram under Islamic religious rules. The council urged the Industry Ministry to prohibit the issuance of vape industry permits and review licensing policies, while calling on the president and parliament to enact a comprehensive ban. On November 10, the Constitutional Court heard a challenge to provisions of the 2023 Health Law seeking a prohibition on vape production, importation, distribution and use. The Health Ministry said on November 11 it was studying stronger restrictions, including a possible ban on circulation, while industry association APVI called for tighter oversight rather than a total ban. Indonesia's Industry Ministry previously estimated the sector comprises about 200 companies, Rp31 trillion ($1.7 billion) in cumulative investment and approximately 100,000 supply-chain jobs. No nationwide statutory ban has been enacted.
Regulations
Nov.12
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
UK Vape Duty Starts in October as Hayati, DOJO and Others Launch Lower-Capacity Products With Lower Per-Unit Tax
The UK's Vaping Products Duty will take effect on October 1, 2026, at a flat rate of £2.20 per 10ml of vaping liquid. Ahead of implementation, DOJO, PIXL and Hayati have introduced or been reported to be adding lower-capacity tiers alongside larger products. DOJO has added a 6ml BLAST7K Fresh below its 10ml BLAST10K Fresh, PIXL offers both a 12ml 8000 and a 6ml 5K, while retailer Ninja Vapes says Hayati is preparing a 7ml 4K alongside its existing 12ml 6K. The pattern points to a growing lower-capacity tier in the UK market, although the brands have not all explicitly linked the changes to the new duty.
Sep.23
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06